Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (703)	6/27/2003 5:45:05 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

GENMAB FILES CTA FOR HUMAX-EGFR TO TREAT CANCER Summary: Genmab files Clinical Trial Application (CTA) to start open label Phase I/II clinical trial using HuMax-EGFr to treat head and neck cancer Copenhagen, Denmark; June 27, 2003 – Genmab A/S (CSE: GEN) announced today it had filed a CTA in Europe to start an open label Phase I/II clinical trial using HuMax-EGFr to treat patients suffering from head and neck cancer. The trial is expected to include fewer than 40 patients, and will be a dose escalation study. The primary endpoint will be to assess the safety of the treatment and the secondary endpoint to assess the efficacy of HuMax-EGFr. Genmab will work with the DAHANCA group (Danish Head and Neck Cancer Group), an organization which is in contact with all patients suffering from head and neck cancer in Denmark, in order to identify potential trial participants. About HuMax-EGFr HuMax-EGFr is a human antibody that targets the Epidermal Growth Factor Receptor, a molecule found in abundance on the surface of many cancer cells. In vivo mouse studies have shown that HuMax-EGFr is capable of inhibiting tumor growth as well as eradicating certain established tumors. Data presented in February by Genmab showed that HuMax-EGFr effectively engages immune effector mechanisms. A combination of laboratory and animal disease model results showed that HuMax-EGFr interrupts the cell signaling that causes tumor cell killing by antibody dependent cellular cytotoxicity, blocks the binding growth factors to tumor cells and directly slows the rate of tumor growth.